3Purrello F, Rabuazza AM. Metabolic factors that affect betacell function and survival. Diabet Nutr Metab, 2000, 13: 84-91.
4Sivitz WI. Lipotoxieity and glueotoxieity in type 2 diabetes. Effects on development and progression. Postgrad Med, 2001,109: 55-59,63-64.
5Lenhard M J, Reeves GD. Continous subcutaneous insulin infusion: a comprehensive review of insulin pump therapy. Arch Intern Med,2001,161: 2293-2300.
6Dupuy O, Mayaudon H, Palou M, et al. Optimized transient insulin infusion in uneontrolled type 2 Diabetes : Evaluation of a pragmatie attitude. Diabet Med, 2000,26 : 371-375.
7Valensi P, Moura I, Magoarou M,et al. Short-term effects of continuous subcutaneous insulin infusion treatment on insulin secretion in non-insulin-dependent overweight patients with poor glycaemic control despite maximal oral anti-diabetic treatment. Diabet Metab,1997,23: 51-57.
8Lormeau B, Aurousseau MH, Valensi P, et al. Hyperinsulinemia and hypofibrinolysis: effects of short-term optimized glyeemic control with contineuous insulin infusion in type Ⅱ diabetie patients. Metabolism,1997,46: 1074-1079.
9Ilkova H, Glaser B, Tunckale A, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care, 1997,20:1353-1356.
10Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 2001,44:929-945.
3McSo dey PT, Bell PM, Jacobsen LV, et al. Tw ice daily b iphasic insulin aspart 30 versus biphasic human insulin 30:a double blind crossover study ing in adults wit h type 2 diabetes mellitus[J]. Olin Ther.2002 24(4):550-559.
